SCHEMBL78938

SCHEMBL78938

CCCCCCCCN(CCCCCCCC)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.52
CA1 P00915 3/20 0.52
CA9 Q16790 3/20 0.52
CA2 P00918 1/20 0.52
GPR84 Q9NQS5 7/20 0.48
PPARG P37231 7/20 0.48
PPARD Q03181 7/20 0.48
PPARA Q07869 7/20 0.48
HDAC11 Q96DB2 5/20 0.48
TSHR P16473 4/20 0.48
PTPN1 P18031 3/20 0.48
ALDH1A1 P00352 2/20 0.48
TLR2 O60603 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
FABP4 P15090 2/20 0.48
SLC22A6 Q4U2R8 1/20 0.48
SLC22A8 Q8TCC7 1/20 0.48
MEN1 O00255 1/20 0.48
ESR1 P03372 1/20 0.48
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4623978 1.00 CA12 (0.52) CA12CA1CA9CA2GPR84
SCHEMBL14763241 1.00 CA12 (0.52) CA12CA1CA9CA2GPR84
SCHEMBL14763841 1.00 CA12 (0.52) CA12CA1CA9CA2GPR84
SCHEMBL25272614 1.00 CA12 (0.52) CA12CA1CA9CA2GPR84
SCHEMBL1416383 1.00 CA12 (0.52) CA12CA1CA9CA2GPR84
SCHEMBL25230061 1.00 CA12 (0.52) CA12CA1CA9CA2GPR84
SCHEMBL4622713 1.00 CA12 (0.52) CA12CA1CA9CA2GPR84
SCHEMBL7652815 1.00 CA12 (0.52) CA12CA1CA9CA2GPR84
SCHEMBL4623644 1.00 CA12 (0.52) CA12CA1CA9CA2GPR84
SCHEMBL4624057 1.00 CA12 (0.52) CA12CA1CA9CA2GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1072 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024158042-A1 COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER 富士フイルム株式会社 2024-08-02 WO disclosed
US-11993697-B2 Flexible tube for endoscope, endoscopic medical device, and resin composition for covering flexible tube substrate for endoscope FUJIFILM CORPORATION (JP) 2024-05-28 US disclosed
WO-2024085172-A1 LIGHT ABSORPTION FILTER, OPTICAL FILTER AND METHOD FOR PRODUCING SAME, ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE, INORGANIC ELECTROLUMINESCENT DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE 富士フイルム株式会社 2024-04-25 WO disclosed
WO-2024085171-A1 LIGHT ABSORPTION FILTER, OPTICAL FILTER AND METHOD FOR PRODUCING SAME, ORGANIC ELECTROLUMINESCENT DISPLAY DEVICE, INORGANIC ELECTROLUMINESCENT DISPLAY DEVICE, AND LIQUID CRYSTAL DISPLAY DEVICE 富士フイルム株式会社 2024-04-25 WO disclosed
US-11958959-B2 Lens for spectacles and spectacles FUJIFILM CORPORATION (JP) 2024-04-16 US disclosed
US-20240084106-A1 KNEADED MATERIAL, METHOD OF PRODUCING KNEADED MATERIAL, MOLDED BODY, AND OPTICAL MEMBER FUJIFILM CORPORATION (JP) 2024-03-14 US disclosed
US-20240067846-A1 PHOTOPOLYMERIZABLE COMPOSITION, CURED SUBSTANCE, AND OPTICAL MEMBER FUJIFILM CORPORATION (JP) 2024-02-29 US disclosed
US-20240051916-A1 METHOD FOR PRODUCING N-(HETERO)ARYL (METH)ACRYLAMIDE COMPOUND FUJIFILM CORPORATION (JP) 2024-02-15 US disclosed
WO-2024024438-A1 CLATHRATE COMPOUND AND METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, RESIN COMPOSITION, POLYMER, CURED PRODUCT, AND LAMINATE 富士フイルム株式会社 2024-02-01 WO disclosed
EP-3421548-B1 COLORING COMPOSITION, INKJET RECORDING INK, INKJET RECORDING METHOD, AND INKJET PRINTER CARTRIDGE FUJIFILM CORP (JP) 2024-01-24 EP disclosed
EP-1139164-A1 Silver halide photographic material FUJI PHOTO FILM CO., LTD. (JP) 2001-10-04 EP disclosed
EP-1132770-A2 Silver halide photographic light-sensitive material Fuji Photo Film Co., Ltd. (JP) 2001-09-12 EP disclosed
EP-1067430-A1 Silver halide photographic emulsion and photographic light-sensitive material using the same FUJI PHOTO FILM CO., LTD. (JP) 2001-01-10 EP disclosed
EP-1033621-A1 Silver halide color photosensitive material and color image forming method using the same FUJI PHOTO FILM CO., LTD. (JP) 2000-09-06 EP disclosed
EP-0885239-A1 NOVEL STEROID CARBAMATES AS POTENTIATING AGENTS Batra, Satish (SE) 1998-12-23 EP disclosed
WO-1997027211-A1 NOVEL STEROID CARBAMATES AS POTENTIATING AGENTS BATRA SATISH (SE) 1997-07-31 WO disclosed
EP-0386508-A1 Quaternary ammonium salts, process for their preparation and their use DEGUSSA AKTIENGESELLSCHAFT (DE) 1990-09-12 EP disclosed
EP-0386509-A1 Biocidal compositions Degussa Aktiengesellschaft (DE) 1990-09-12 EP disclosed
US-4333868-A Phosphite ester stabilizers CIBA-GEIGY CORPORATION (US) 1982-06-08 US disclosed
US-4132702-A Phenol esters and amides and polymers stabilized therewith CIBA-GEIGY CORPORATION (US) 1979-01-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240051916-A1 METHOD FOR PRODUCING N-(HETERO)ARYL (METH)ACRYLAMIDE COMPOUND NAT1, AHR, PAM CA12 4473/4885CA1 4202/4885CA9 3288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.